Involvement of HER-2/neu and metastasis-related proteins in the development of ileal neuroendocrine tumors

Virchows Archiv

Volumn 458, Issue 5, 2011, Pages 525-536

  Azzoni, Cinzia ^a   Bottarelli, Lorena ^a   Cecchini, Stefano ^b   Lagrasta, Costanza ^a   Pizzi, Silvia ^a   D'Adda, Tiziana ^a   Tamburini, Elisa ^a   Rindi, Guido ^c   Bordi, Cesare ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b Laboratory of Clinical Pharmacology   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

c Met; HER2 neu; Ileal neuroendocrine tumors; MTA 1; Polysomy; VEGF

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN MTA 1; SCATTER FACTOR RECEPTOR; TUMOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CHROMOSOME 17; CLINICAL ARTICLE; CLINICAL FEATURE; CYTOPLASM; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ILEUM TUMOR; IMMUNOHISTOCHEMISTRY; MALE; NEUROENDOCRINE TUMOR; POLYSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; TUMOR GROWTH;

ANTIBODIES, MONOCLONAL; GENE AMPLIFICATION; GENES, ERBB-2; HISTONE DEACETYLASES; HUMANS; ILEAL NEOPLASMS; IN SITU HYBRIDIZATION, FLUORESCENCE; NEUROENDOCRINE TUMORS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, ERBB-2; REPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79956210515     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-011-1069-y     Document Type: Article

References (73)

1. Tonnies H, Toliat MR, Ramel C et al (2001) Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation. Gut 48:536-541
2. Leotlela PD, Jauch A, Holtgreve-Grez H, Thakker RV (2003) Genetics of neuroendocrine and carcinoid tumours. Endocr Relat Cancer 10:437-450
3. Modlin IM, Kidd M, Latich I et al (2005) Current status of gastrointestinal carcinoids. Gastroenterology 128:1717-1751
4. Oberg K (2002) Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment. Curr Opin Oncol 14:38-45
5. Hung MC, Lau YK (1999) Basic science of HER-2/neu: a review. Semin Oncol 26:51-59
6. Kaptain S, Tan LK, Chen B (2001) Her-2/neu and breast cancer. Diagn Mol Pathol 10:139-152
7. Tapia C, Glatz K, Novotny H et al (2007) Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Mod Pathol 20:192-198
8. Ross JS, McKenna B (2001) The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Investig 19:554-568
9. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182
10. Zhau HE, Wan DS, Zhou J, Miller GJ, von Eschenbach AC (1992) Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines. Mol Carcinog 5:320-327
11. Balañá ME, Labriola L, Salatino M et al (2001) Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene 20:34-47
12. Tolgay OI, Dolled-Filhart M, D'Aquila TG, Camp RL, Rimm DL (2003) Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 97:1841-1848
13. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21:3995-4004
14. Katoh R (2003) Angiogenesis in endocrine glands: special reference to the expression of vascular endothelial growth factor. Microsc Res Tech 60:181-185
15. Shattuck DL, Miller JK, Carraway KL 3rd, Sweeney C (2008) Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 68:1471-1477
16. Khoury H, Naujokas MA, Zuo D et al (2005) HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol Biol Cell 16:550-561
17. Mazumdar A, Wang RA, Mishra SK et al (2001) Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 3:30-37
18. Toh Y, Pencil SD, Nicolson GL (1994) A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. J Biol Chem 269:22958-22963
19. Mahoney MG, Simpson A, Jost M et al (2002) Metastasis-associated protein (MTA)1 enhances migration, invasion, and anchorage-independent survival of immortalized human keratinocytes. Oncogene 21:2161-2170
20. Petit AM, Rak J, Hung MC et al (1997) Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151 (6):1523-1530
21. Bosman F, Carneiro F, Hruban R, Theise N (2010) WHO classification of tumours of the digestive system. IARC, Lyon
22. Rindi G, Klöppel G, Couvelard A et al (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451:757-762 (Pubitemid 47497934)
23. Kim R, Arihiro K, Emi M, Tanabe K, Osaki A (2006) Potential role of HER-2; in primary breast tumor with bone metastasis. Oncol Rep 15:1477-1484
24. Duncan TJ, Al-Attar A, Rolland P et al (2008) Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res 14:3030-3035
25. Balasenthil S, Broaddus RR, Kumar R (2006) Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas. Hum Pathol 37:656-661 (Pubitemid 43956542)
26. Birner P, Oberhuber G, Stani J et al (2001) Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 7:1669-1675 (Pubitemid 32708634)
27. Seiwert TY, Jagadeeswaran R, Faoro L et al (2009) The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 69:3021-3031
28. Li SH, Wang Z, Liu XY (2009) Metastasis-associated protein 1 (MTA1) overexpression is closely associated with shorter disease-free interval after complete resection of histologically node-negative esophageal cancer. World J Surg 33:1876-1881
29. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T (1986) The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644-1646 (Pubitemid 16095607)
30. Aasland R, Lillehaug JR, Male R et al (1988) Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB. Br J Cancer 57:358-363
31. Wang DG, Johnston CF, Buchanan KD (1997) Oncogene expression in gastroenteropancreatic neuroendocrine tumors: implications for pathogenesis. Cancer 80:668-675 (Pubitemid 27339821)
32. Yamaguchi M, Hirose K, Hirai N (2007) HER2 expression in gastrointestinal carcinoid tumors: high in intestinal but not in gastric tumors. Surg Today 37:270-271 (Pubitemid 46365461)
33. Xia W, Lau YK, Zhang HZ et al (1999) Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 5:4164-4174
34. Lambropoulou M, Stefanou D, Alexiadis G et al (2007) Cytoplasmic expression of c-erb-B2 in endometrial carcinomas. Onkologie 30:495-500 (Pubitemid 47462059)
35. Gusterson BA, Gullick WJ, Venter DJ et al (1987) Immunohistochemical localization of c-erbB-2 in human breast carcinomas. Mol Cell Probes 1:383-391
36. Soda G, Antonaci A, Bosco D, Nardoni S, Melis M (1999) Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas. J Exp Clin Cancer Res 18:363-367
37. de Krijger RR, van der Harst E, van der Ham F et al (1999) Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas. J Pathol 188:51-55
38. Potti A, Willardson J, Forseen C et al (2002) Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma. Lung Cancer 36:257-261 (Pubitemid 34497123)
39. Park DI, Yun JW, Park JH et al (2006) HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 51:1371-1379 (Pubitemid 44315804)
40. Koeppen HK, Wright BD, Burt AD et al (2001) Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology 38:96-104 (Pubitemid 32194449)
41. Cavalot A, Martone T, Roggero N et al (2007) Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck 29:655-664 (Pubitemid 47168236)
42. Park DI, Kang MS, Oh SJ et al (2007) HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis 22:491-497 (Pubitemid 46488053)
43. Verri E, Guglielmini P, Puntoni M et al (2005) HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clin Study Oncol 68:154-161 (Pubitemid 41158970)
44. Ezzat S, Zheng L, Smyth HS, Asa SL (1997) The c-erbB-2/neu proto-oncogene in human pituitary tumours. Clin Endocrinol (Oxf) 46:599-606 (Pubitemid 27286933)
45. Bieche I, Franc B, Vidaud D, Vidaud M, Lidereau R (2001) Analyses of MYC. ERBB2, and CCND1 genes in benign and malignant thyroid follicular cell tumors by real-time polymerase chain reaction. Thyroid 11:147-152
46. Schneider PM, Hung MC, Chiocca SM et al (1989) Differential expression of the c-erbB-2 gene in human small cell and nonsmall cell lung cancer. Cancer Res 49:4968-4971 (Pubitemid 19239327)
47. Pelosi G, Del Curto B, Dell'Orto P et al (2005) Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. Int J Cancer 113:101-108 (Pubitemid 39507316)
48. Kuhn EJ, Kurnot RA, Sesterhenn IA, Chang EH, Moul JW (1993) Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol 150:1427-1433 (Pubitemid 24356189)
49. Mellon JK, Lunec J, Wright C et al (1996) C-erbb-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol 155:321-326 (Pubitemid 126426487)
50. Salido M, Tusquets I, Corominas JM et al (2005) Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res 7:R267-R273
51. Downs-Kelly E, Yoder BJ, Stoler M et al (2005) The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol 29:1221-1227 (Pubitemid 41232996)
52. Hyun CL, Lee HE, Kim KS et al. (2007) The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol
53. Latif Z, Watters AD, Dunn I et al (2004) HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 40:56-63 (Pubitemid 37542318)
54. Cianciulli AM, Guadagni F, Marzano R et al (2003) HER-2/neu oncogene amplification and chromosome 17 aneusomy in endometrial carcinoma: correlation with oncoprotein expression and conventional pathological parameters. J Exp Clin Cancer Res 22:265-271 (Pubitemid 36734185)
55. Nahtaa R, Estevaa FJ (2006) Herceptin: mechanisms of action and resistance. Cancer Lett 232:123-138
56. Wolff AC, Hammond ME, Schwartz JN et al (2007) Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145
57. Hofmann M, Stoss O, Gaiser T et al (2008) Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin(R)) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol 61:89-94 (Pubitemid 351158232)
58. Kiewe P, Hasmuller S, Kahlert S et al (2006) Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 12:3085-3091 (Pubitemid 43837355)
59. Kiewe P, Thiel E (2008) Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs 17:1553-1558
60. Bianco AR (2004) Targeting c-erbB2 and other receptors of the c-erbB family: rationale and clinical applications. J Chemother 16:52-54
61. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925 (Pubitemid 37493640)
62. Di Renzo MF, Olivero M, Giacomini A et al (1995) Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1:147-154
63. Takeuchi H, Bilchik A, Saha S et al (2003) c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res 9:1480-1488 (Pubitemid 36418405)
64. Xue Y, Wong J, Moreno GT et al (1998) NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Mol Cell 2:851-861 (Pubitemid 128378992)
65. Toh Y, Oki E, Oda S et al (1997) Overexpression of the MTA1 gene in gastrointestinal carcinomas: correlation with invasion and metastasis. Int J Cancer 74:459-463 (Pubitemid 27400170)
66. Toh Y, Kuwano H, Mori M, Nicolson GL, Sugimachi K (1999) Overexpression of metastasis-associated MTA1 mRNA in invasive oesophageal carcinomas. Br J Cancer 79:1723-1726 (Pubitemid 29132295)
67. Nawa A, Nishimori K, Lin P et al (2000) Tumor metastasis-associated human MTA1 gene: its deduced protein sequence, localization, and association with breast cancer cell proliferation using antisense phosphorothioate oligonucleotides. J Cell Biochem 79:202-212
68. Iguchi H, Imura G, Toh Y, Ogata Y (2000) Expression of MTA1, a metastasis-associated gene with histone deacetylase activity in pancreatic cancer. Int J Oncol 16:1211-1214
69. Sasaki H, Moriyama S, Nakashima Yet al (2002) Expression of the MTA1 mRNA in advanced lung cancer. Lung Cancer 35:149-154 (Pubitemid 34136092)
70. Sasaki H, Yukiue H, Kobayashi Y et al (2001) Expression of the MTA1 mRNA in thymoma patients. Cancer Lett 174:159-163 (Pubitemid 33022675)
71. Hofer MD, Chang MC, Hirko KA, Rubin MA, Nosé V (2009) Immunohistochemical and clinicopathological correlation of the metastasis-associated gene 1 (MTA1) expression in benign and malignant pancreatic endocrine tumors. Mod Pathol 22:933-939
72. Kidd M, Modlin IM, Mane SM et al (2006) The role of genetic markers - NAP1L1, MAGE-D2, and MTA1 - in defining small-intestinal carcinoid neoplasia. Ann Surg Oncol 13:253-262
73. Rindi G, Klöppel G, Alhman H et al (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395-401 (Pubitemid 44451313)